Form 4: Royalty Pharma CFO Executes Planned Share Sale

EVP & CFO Terrance P. Coyne sold 64,399 Class A Ordinary Shares of Royalty Pharma plc via a pre-arranged 10b5-1 trading plan.

Summary

• Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, sold 64,399 Class A Ordinary Shares on May 26, 2026.
• The shares were sold at a weighted average price of $53.9778 per share, with individual transaction prices ranging from $53.64 to $54.63.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 24, 2026.
• Following the transaction, the reporting person retains significant indirect holdings, including interests exchangeable into over 8.2 million Class A Ordinary Shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and does not reflect a change in the executive's outlook on the company.

Positives

• The sale was conducted under a pre-established 10b5-1 plan, indicating the transaction was scheduled in advance rather than based on non-public information.
• The reporting person maintains a substantial long-term interest in the company through various family vehicles and exchangeable partnership interests.

Negatives

• The sale represents a reduction in the direct and indirect equity stake held by a key executive.

Risks

• Future share price volatility could impact the value of the remaining significant holdings held by the executive.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive sales under 10b5-1 plans are standard corporate practice for liquidity and diversification, and generally do not signal a lack of confidence in the company's long-term prospects.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives to manage equity holdings while maintaining compliance with SEC insider trading regulations.
• The scale of the sale relative to the executive's total beneficial ownership (including exchangeable interests) is consistent with typical executive financial planning.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was executed via a pre-planned mechanism.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Royalty Pharma, RPRX, Insider Trading, Form 4, CFO, 10b5-1